| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | ondansetron (Setofilm®) |
| Formulation | 4 mg and 8 mg orodispersible film |
| Reference number | 2214 |
| Indication | Prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy in adults; prophylaxis and treatment of delayed nausea and vomiting induced by moderately to highly emetogenic chemotherapy in adults; management of chemotherapy-induced nausea and vomiting in children aged ≥6 months; prophylaxis and treatment of acute and delayed nausea and vomiting induced by highly emetogenic radiotherapy in adults; and prophylaxis and treatment of post operative nausea and vomiting in adults and children aged ≥4 years |
| Company | Norgine Pharmaceuticals Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 24/05/2013 |